​

Definium Therapeutics Stock (NASDAQ:DFTX)

FinancialsChartTranscripts
Definium Therapeutics by TradingView

Previous Close

$17.98

52W Range

$12.88 - $19.63

50D Avg

$14.26

200D Avg

$14.26

Market Cap

$1.80B

Avg Vol (3M)

$2.53M

Beta

2.68

Div Yield

-

DFTX Company Profile

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

74

IPO Date

Jan 06, 2026

Website

DFTX Performance

DFTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-166.31M$-103.92M$-93.87M
Net Income$-183.79M$-108.68M$-95.73M
EBITDA$-166.31M$-105.87M$-92.57M
Basic EPS$-2.06$-1.54$-2.44
Diluted EPS$-2.06$-0.15$-2.44

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 26, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM
Q2 25Jul 31, 25 | 4:30 PM

Peer Comparison

TickerCompany
BBOTBridgeBio Oncology Therapeutics Inc.
TNGXTango Therapeutics, Inc.
URGNUroGen Pharma Ltd.
ANABAnaptysBio, Inc.
NRIXNurix Therapeutics, Inc.
RZLTRezolute, Inc.
KODKodiak Sciences Inc.
XNCRXencor, Inc.
FTREFortrea Holdings Inc.
SVRASavara Inc.